AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously Presented) A pharmaceutical composition comprising, separately or together, an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β_2 adrenoreceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts for simultaneous, sequential or separate administration by inhalation in the treatment of asthma bronchiale in mammals.

2. (Previously Presented) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) formoterol.

3. (Previously Presented) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) salmeterol.

4. (Previously Presented) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) reproterol.

5. (Canceled).

6. (Canceled).

7. (Previously Presented) A method for the treatment of asthma bronchiale, comprising administering to a patient in need of such treatment an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts, if appropriate together

with pharmaceutically acceptable excipients or vehicles, for simultaneous, sequential or separate administration.

8. (Previously Presented) A process for the preparation of a pharmaceutical composition for the treatment of asthma bronchiale, comprising an effective amount of the active compound loteprednol or loteprednol etabonate and at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts, wherein loteprednol or loteprednol etabonate and the β_2 adrenoceptor agonist or the β_2 adrenoceptor agonists are mixed individually or together, if appropriate together with pharmaceutically acceptable excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.